These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 14974022

  • 21. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.
    Sandborn WJ.
    Curr Gastroenterol Rep; 2003 Dec; 5(6):501-5. PubMed ID: 14602060
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Strategies targeting tumor necrosis factor in Crohn's disease.
    Sandborn WJ.
    Acta Gastroenterol Belg; 2001 Dec; 64(2):170-2. PubMed ID: 11475128
    [Abstract] [Full Text] [Related]

  • 25. Cyclosporine for induction of remission in Crohn's disease.
    McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK.
    Cochrane Database Syst Rev; 2005 Apr 18; (2):CD000297. PubMed ID: 15846602
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
    Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF.
    Clin Gastroenterol Hepatol; 2008 Jun 18; 6(6):644-53. PubMed ID: 18550004
    [Abstract] [Full Text] [Related]

  • 27. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Biomed Pharmacother; 2007 Jan 18; 61(1):75-80. PubMed ID: 17184965
    [Abstract] [Full Text] [Related]

  • 28. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J.
    Gut; 2004 Oct 18; 53(10):1485-93. PubMed ID: 15361500
    [Abstract] [Full Text] [Related]

  • 29. Glutamine for induction of remission in Crohn's disease.
    Akobeng AK, Elawad M, Gordon M.
    Cochrane Database Syst Rev; 2016 Feb 08; 2(2):CD007348. PubMed ID: 26853855
    [Abstract] [Full Text] [Related]

  • 30. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.
    Cochrane Database Syst Rev; 2014 Sep 29; (9):CD010455. PubMed ID: 25264908
    [Abstract] [Full Text] [Related]

  • 31. Enteral nutrition for maintenance of remission in Crohn's disease.
    Akobeng AK, Thomas AG.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD005984. PubMed ID: 17636816
    [Abstract] [Full Text] [Related]

  • 32. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D, Macdonald JK, Chande N.
    Cochrane Database Syst Rev; 2014 Feb 21; (2):CD010410. PubMed ID: 24558033
    [Abstract] [Full Text] [Related]

  • 33. Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.
    Srinivasan R, Akobeng AK.
    Cochrane Database Syst Rev; 2009 Apr 15; (2):CD007350. PubMed ID: 19370684
    [Abstract] [Full Text] [Related]

  • 34. Enteral nutritional therapy for induction of remission in Crohn's disease.
    Zachos M, Tondeur M, Griffiths AM.
    Cochrane Database Syst Rev; 2007 Jan 24; (1):CD000542. PubMed ID: 17253452
    [Abstract] [Full Text] [Related]

  • 35. Antibiotics for induction and maintenance of remission in Crohn's disease.
    Townsend CM, Parker CE, MacDonald JK, Nguyen TM, Jairath V, Feagan BG, Khanna R.
    Cochrane Database Syst Rev; 2019 Feb 07; 2(2):CD012730. PubMed ID: 30731030
    [Abstract] [Full Text] [Related]

  • 36. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM, Perry CM.
    BioDrugs; 2002 Feb 07; 16(2):111-48. PubMed ID: 11985485
    [Abstract] [Full Text] [Related]

  • 37. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.
    Health Technol Assess; 2007 Aug 07; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A.
    Aliment Pharmacol Ther; 2006 Mar 01; 23(5):617-28. PubMed ID: 16480401
    [Abstract] [Full Text] [Related]

  • 40. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.
    Rutgeerts PJ.
    Aliment Pharmacol Ther; 1999 Sep 01; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.